Jean Holloway Sells 5,761 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 5,761 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total transaction of $264,199.46. Following the sale, the senior vice president owned 163,408 shares of the company’s stock, valued at $7,493,890.88. This represents a 3.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Artivion Trading Up 0.3%

AORT opened at $45.71 on Friday. The stock has a market capitalization of $2.17 billion, a PE ratio of -108.84 and a beta of 1.65. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The business’s 50 day moving average price is $42.69 and its 200 day moving average price is $36.27.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company’s quarterly revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd increased its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the period. MCF Advisors LLC grew its stake in Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the period. State of Wyoming acquired a new stake in Artivion in the 3rd quarter valued at about $80,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Artivion in the 3rd quarter valued at about $92,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AORT shares. JMP Securities increased their target price on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Citigroup restated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Oppenheimer reiterated an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. LADENBURG THALM/SH SH lowered Artivion from a “buy” rating to a “neutral” rating and boosted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Artivion has an average rating of “Moderate Buy” and an average price target of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.